Avoro Capital

Trouble builds for Merck's $11.5B Acceleron buy as activist investor behind Gilead's Immunomedics deal says too early, too cheap
Fierce Pharma
Fri, 10/1/21 - 10:55 am
Merck
Acceleron
M&A
investors
Avoro Capital